11th Circ. AndroGel Decision Bolsters FTC Pay-For-Delay Case
The Eleventh Circuit on Thursday refused a bid by an Abbott Laboratories subsidiary to seal a proprietary financial analysis for its AndroGel drug, a decision that allows the Federal Trade Commission...To view the full article, register now.
Already a subscriber? Click here to view full article